A claims-based Markov model for Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 3, 2010, Pages 448-458

  Malone, D C ^a   Waters, H C ^b   Van Den Bos, J ^c   Popp, J ^b   Draaghtel, K ^c   Rahman, M I ^d  

^a UNIVERSITY OF ARIZONA   (United States)

^b CENTOCOR INC   (United States)

^c MILLIMAN INC   (United States)

^d Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BILLING AND CLAIMS; CROHN DISEASE; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROHN DISEASE; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; YOUNG ADULT;

EID: 77954332544     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04356.x     Document Type: Article

References (27)

1. Loftus EV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002 16:51 60.
2. Loftus EV Jr., Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998 114:1161 1168.
3. Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn's disease. Ailment Pharmacol Ther 2007 25:861 870.
4. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007 5:1424 1429.
5. Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992 14:309 317.
6. Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol 2000 95:1955 1960.
7. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999 117:49 57.
8. Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohn's disease. Am J Gastroenterol 2000 95:524 530.
9. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009 30:264 274.
10. Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2001 96:635 643.
11. Gregor JC, McDonald JWD, Klar N, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997 3:265 276.
12. Clark W, Raftery J, Song F, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technol Assess 2003 7 (3).
13. Drummond MF. Methods for economic appraisal of health technology. In:M.F Drummond. ed. Economic Appraisal of Health Technology in the European Community.
14. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Programmes.
15. Pascua M, Su C, Lewis JD, Brensinger C, Lichtenstein GR. Meta-analysis: factors predicting postoperative recurrence with placebo therapy in patients with Crohn's disease. Aliment Pharmacol Ther 2008 28:545 556.
16. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990 99:956 963.
17. Penner RM, Madsen KL, Fedorak RN. Postoperative Crohn's disease. Inflamm Bowel Dis 2005 11:765 777.
18. Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. Inflamm Bowel Dis 2009 15:1460 1466.
19. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009 15:1295 1301.
20. Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999 42:347 356.
21. Jaisson-Hot I, Descos BFL, Colin C. Management for severe Crohn's disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care 2004 20:274 279.
22. Kennedy ED, Urbach DR, Krahn MD, et al. Azathioprine or ileocolic resection for steroid-dependent terminal ileal Crohn's disease? A Markov analysis. Dis Colon Rectum 2004 47:2120 2130.
23. Lindsay J, Punekar YS, Morris J, Chung-Faye J. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease - modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther 2008 28:76 87.
24. Keighley MRB, Stockbrugger RW. Inflammatory bowel disease. Aliment Pharmacol Ther 2003 18:66 70.
25. Wyke R, Edwards F, Allan R. Employment problems and prospects for patients with inflammatory bowel disease. Gut 1988 29:1229 1235.
26. Feagan BG, Bala M, Yan S, et al. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol 2005 39:390 396.
27. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004 99:91 6.